Infliximab use in Crohn’s disease

Author： Bewtra Meenakshi   Lichtenstein Gary R  

Publisher： Informa Healthcare

ISSN： 1471-2598

Source： Expert Opinion on Biological Therapy, Vol.5, Iss.4, 2005-04, pp. : 589-599

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Antitumour necrosis factor therapy in Crohn’s disease

By Kaser Arthur   Tilg Herbert  

Expert Opinion on Biological Therapy, Vol. 2, Iss. 7, 2002-10 ,pp. : 715-721

Informa Healthcare

Access to resources Recommend Favorite

Biological response modifiers for the treatment of Crohn’s disease

By Siveke J   Folwaczny C  

Expert Opinion on Biological Therapy, Vol. 4, Iss. 11, 2004-11 ,pp. : 1719-1727

Informa Healthcare

Access to resources Recommend Favorite

A comparative analysis of the molecular genetic processes in the pathogenesis of psoriasis and Crohn’s disease

By Piruzian E.   Ishkin A.   Nikol’skaya T.   Abdeev R.   Bruskin S.  

Molecular Biology, Vol. 43, Iss. 1, 2009-02 ,pp. : 159-165

MAIK Nauka/Interperiodica

Access to resources Recommend Favorite

Teduglutide in Crohn's disease

By Blonski Wojciech  

Expert Opinion on Biological Therapy, Vol. 13, Iss. 8, 2013-12 ,pp. : 1207-1214

Informa Healthcare

Access to resources Recommend Favorite

Vedolizumab for Crohn's disease

By Mosli Mahmoud H   Feagan Brian G  

Expert Opinion on Biological Therapy, Vol. 13, Iss. 3, 2013-03 ,pp. : 455-463

Informa Healthcare

Access to resources Recommend Favorite